NCT00893984View on ClinicalTrials.gov

Alternative in Beta Blocker Intolerance: The ABBI Trial

PHASE4TerminatedINTERVENTIONAL

Enrollment

6

Participants

Timeline

Start Date

May 31, 2009

Primary Completion Date

June 30, 2012

Study Completion Date

June 30, 2012

Conditions

Coronary Artery Disease

Interventions

DRUG

Nebivolol

Bystolic (Nebivolol), 5 mg per day for 30 days, titrated up to 10 mg at 2 weeks if necessary for blood pressure control.

Trial Locations (1)

55407

Minneapolis Heart Institute at Abbott Northwestern Hospital, Minneapolis

Sponsors

Collaborators (1)

Forest Laboratories

All Listed Sponsors

collaborator

Forest Laboratories

INDUSTRY

lead

Minneapolis Heart Institute Foundation

OTHER